triple strength l-carnitine Signature Carnitine by Bodybuilding.com As individuals vary so may results from using this product. 3 L-Carnitine 3000 Liquid

NAD+ & cellular metabolism Explored in cell research on how NNMT inhibition affects NAD+ and SAM levels investigational, animal and in-vitro only

10.1007/s00726-009-0269-0 133 WuJ.LiZ.YangZ.GuoL.ZhangY.DengH.et al (2018)

Acetyl L-Carnitine HCl 1000mg Supplement Facts

Additionally, obesity itself can contribute to gut dysbiosis, creating a vicious cycle

Supplement Facts: Serving Size: 2.5 g (approximately 1/2 scoop) Servings Per Container: 100 Amount Per Serving: AAKG (Arginine Alpha-Ketoglutarate): 2000 mg Taurine: 250 mg Calories: 0 kcal Energy kJ: 0 kJ Protein: 0 g Carbohydrate: 0 g of which sugars: 0 g Fat: 0 g of which saturates: 0 g Fibre: 0 g Salt: 0 g *RI - Reference Intake Ingredients: L-Arginine Alpha-Ketoglutarate (AAKG), Taurine, Stabilizing Agent: Gum Arabic, Acidity Regulator: Malic Acid, Flavoring, Sweetener: Sucralose

Structure: H-D-Arg-2,6-diMe-L-Tyr-L-Lys-L-Phe-NH2 (C-terminal amidation) Indication: First therapy approved to improve muscle strength in BTHS patients Mechanism: Targets mitochondrial dysfunction underlying skeletal muscle weakness and cardiomyopathy FDA Approved Peptides by Therapeutic Category Metabolic & Endocrine Peptides (GLP-1 & GIP) The metabolic peptide sector dominates current prescribing patterns, with the GLP-1 receptor agonist class leading unprecedented demand: Peptide (Brand) Indication FDA Approval Manufacturer Semaglutide (Ozempic/Wegovy) Type 2 diabetes, Weight management, CVD risk 2017/2021 Novo Nordisk Tirzepatide (Mounjaro/Zepbound) Type 2 diabetes, Obesity 2022/2023 Eli Lilly Liraglutide (Victoza/Saxenda) Type 2 diabetes, Weight management 2010/2014 Novo Nordisk Dulaglutide (Trulicity) Type 2 diabetes, CVD risk reduction 2014 Eli Lilly Exenatide (Byetta/Bydureon) Type 2 diabetes 2005 AstraZeneca Lixisenatide (Adlyxin) Type 2 diabetes 2016 Sanofi Pramlintide (Symlin) Type 1 & 2 diabetes adjunct 2005 N/A 2026 Pipeline Update: Tirzepatide is under FDA review for pediatric indications with decisions expected in 2026, while semaglutide 7.2 mg and combination therapies (cagrilintide + semaglutide) are advancing through late-stage development